drugset / Trial / NCT06148636
A Safety Study of 212Pb-VMT-alpha-NET in Patients With Neuroendocrine Tumors
Phase 0
Active not recruiting
24 enrolled
David Bushnell
Holden Comprehensive Cancer Center · collabNational Cancer Institute (NCI) · collabPerspective Therapeutics · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a safety study to determine the recommended dose to test in clinical trials. The study involves two treatments with 212Pb (212-lead) VMT-α-NET. This is a safety study only; it will most likely not provide therapeutic benefit.
Timeline
- Start
- 2023-11-10
- Primary completion
- 2026-12-31
- Completion
- 2027-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | [212Pb]VMT-α-NET | Peptide | 200 unknown | Other |
| Subject | [212Pb]VMT-α-NET | Peptide | 350 unknown | Other |
| Subject | [212Pb]VMT-α-NET | Peptide | 600 unknown | Other |
| Subject | [212Pb]VMT-α-NET | Peptide | 810 unknown | Other |
| Subject | [212Pb]VMT-α-NET | Peptide | 1050 unknown | Other |